From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.
|
Synonyms: DAB389 IL2 | denileukin diftitox-cxdl | LY 335348 | Lymphir® | Ontak®
denileukin diftitox is an approved drug (FDA (1999))
Compound class:
Peptide
Comment: Denileukin diftitox is an anti-cancer immunotherapy drug that was designed to target and eradicate malignant (IL-2 receptor-expressing) T cells. It is a recombinant protein containing peptide sequences of both interleukin-2 and diphtheria toxin [1,5]. It simultaneously directly kills IL-2R expressing tumour cells and promotes depletion of host Treg cells which enhances the immune response
|
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Cutaneous T cell lymphoma |
Disease Ontology:
DOID:0060061 |
Approved drug for CTCL. | |
